查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1992164

DNA诊断市场：按技术、应用、产品类型和最终用户划分－2026-2032年全球市场预测

DNA Diagnostics Market by Technology, Application, Product Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

DNA诊断市场预计到2025年将达到135.9亿美元，到2026年将成长到147.7亿美元，到2032年将达到257亿美元，复合年增长率为9.52%。

主要市场统计数据
基准年 2025 135.9亿美元
预计年份：2026年 147.7亿美元
预测年份 2032 257亿美元
复合年增长率 (%) 9.52%

本书以现代视角介绍了 DNA 诊断生态系统，重点关注科学进步、监管变化和营运压力等因素如何重塑诊断决策。

本导论整体情况了现代DNA诊断技术，重点在于影响诊断实践和研究的科学、监管和技术因素的融合。近年来，定序化学和生物资讯流程的进步显着提升了诊断的处理能力和准确性，同时监管机构也制定了强调分析有效性、临床效用和上市后监管的框架。同时，检查室工作流程也不断调整，以平衡高度复杂的检测与快速出结果和成本控制之间的平衡。

分子技术的融合、临床应用的扩展以及数位平台的整合，正在为诊断和护理路径带来系统性的变革。

在技​​术成熟和临床范式不断演进的推动下，整个DNA诊断生态系统正在经历一场变革性的转变。定序平台，特别是与传统Sanger测序并行使用的次世代定序技术，如今已与聚合酵素链锁反应（PCR）、微阵列技术和萤光杂合反应（FISH）等成熟的分子技术并存，使得检查室能够根据处理能力、分辨率和临床背景选择合适的工具。这些技术选择会影响从样本製备到资料解读的下游工作流程，因此需要同步开发稳健的生物资讯学和品管流程。

评估 2025 年美国关税调整对诊断产业供应链的韧性和采购计画的营运和策略影响。

美国将于2025年实施新的关税措施，将进一步增加DNA诊断领域全球供应链和筹资策略的复杂性。关税变化将改变进口设备、试剂和专用耗材的相对成本结构，进而影响采购决策、库存缓衝以及对本地生产的投资。因此，供应商和检查室营运商需要重新审视供应商协议，评估替代采购途径，并考虑对长期供应商关係的影响。

复杂的細項分析揭示了技术、临床应用、产品阵容和最终用户需求如何全面决定采用轨迹和投资重点。

关键的细分洞察揭示了差异化技术平台、临床应用、产品系列和终端用户类型如何影响技术采纳路径和营运模式。在技​​术层面，萤光杂合反应和微阵列等传统和标靶技术继续应用于特定的诊断领域，而聚合酵素链锁反应(PCR) 则在快速、高灵敏度检测方面保持主导地位。包括次世代定序和桑格定序在内的定序方法正分别扩展到全面的基因组分析和确证检测领域，每种方法都有其独特的处理和资料处理需求。

美洲、欧洲、中东和非洲以及亚太地区在诊断领域的采用、监管和供应策略方面的影响的比较趋势。

区域趋势持续对整个DNA诊断领域的技术应用、监管方式和合作生态系统产生重大影响。在美洲，成熟的临床网络和完善的报销机制支持了先进基因组检测的广泛应用，但成本压力和支付方期望的改变促使人们更加关注检测的效用和运营效率。该地区的临床检查室经常进行跨境采购、合作研究和官民合作关係，以加速转化研究和诊断检验。

在诊断领域采取策略性企业行动，结合研发领导地位、平台整合和合作伙伴关係，以加速临床部署并实现商业性韧性。

DNA诊断领域的公司透过结合技术领先优势、策略伙伴关係和服务导向经营模式来脱颖而出。产业领导企业正大力投资研发，以改善定序化学流程、提高检测灵敏度并简化从检体到结果的工作流程。同时，软体供应商和整合商正专注于云端分析功能、与实验室资讯系统的互通性以及合规的资料管治，以支援多站点部署和符合监管要求的报告。

为领导企业提供切实可行的策略建议，以加强其供应链、整合数位平台，并将临床证据与商业化目标结合。

产业领导企业应采取务实的策略，在短期业务永续营运和长期创新之间取得平衡。首先，他们应优先考虑供应商多元化和灵活的采购条款，以保护其营运免受关税波动和供应链中断的影响。此外，针对高风险耗材和关键设备零件，必须对区域或本地製造能力进行针对性的投资。其次，他们应加快云端服务、数据分析工具和测试资讯管理系统的整合，以缩短测试结果的获取时间，提高品管，并实现可扩展的多站点运作。第三，他们应设计针对特定应用领域（例如带因者筛检、肿瘤检测和传染病检查）的临床证据项目，以满足监管要求和支付者的期望。

一种透明且可重复的研究途径，将与主要相关人员的对话与二手研究相结合，以检验对诊断技术的见解。

本调查方法结合了结构化的初步研究和针对性的二次分析，确保了研究结果的可靠性和可重复性。初步研究数据包括对实验室经理、临床遗传学家、检体采购经理和高级研发主管的详细访谈，以了解营运限制、检验实践和应用驱动因素。除了这些定性调查外，还与仪器开发商和软体供应商举办了研讨会，以评估整合挑战和不断变化的产品蓝图。

一项决定性的整合，强调将技术创新、监管策略和商业性实施相结合，以实现可持续的临床影响。

总之，DNA诊断正处于一个转捩点，需要技术能力、监管进步和商业策略的协调配合才能真正发挥临床价值。优先考虑互通性、严格的临床检验和适应性供应链策略的检查室和产品开发商，将在提供可靠且具有临床应用价值的结果方面超越同行。成熟的分子诊断技术与不断扩展的定序应用之间的相互作用，为创新开闢了多元化的途径，但成功的关键在于将技术进步转化为检验且医保覆盖的临床服务。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：DNA诊断市场：依技术划分

  • 萤光原位杂合反应
  • 微阵列
  • 聚合酵素链锁反应
  • 定序
    • 次世代定序
    • 桑格定序

第九章：DNA诊断市场：依应用领域划分

  • 基因检测
    • 携带者筛检
    • 诊断测试
    • 新生儿筛检
    • 预测性测试
  • 传染病检查
  • 肿瘤科检查
  • 药物基因体学
  • 产前检查

第十章：DNA诊断市场：依产品类型划分

  • 消耗品
  • 装置
  • 成套工具
  • 软体和服务
    • 云端服务
    • 数据分析工具
    • 检查资讯管理系统

第十一章 DNA诊断市场：依最终用户划分

  • 诊断检查室
  • 医院和诊所
  • 研究机构

第十二章 DNA诊断市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 DNA诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 DNA诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国DNA诊断市场

第十六章：中国DNA诊断市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Agilent Technologies, Inc.
  • ARUP Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMerieux
  • Danaher Corporation
  • DNA Diagnostic A/S
  • Eurofins
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Luminex Corporation
  • Myriad Genetics
  • Natera, Inc.
  • Oxford Nanopore Technologies PLC
  • Promega Corporation
  • QIAGEN GmbH
  • Quest Diagnostics
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Veracyte, Inc.
Product Code: MRR-4F7B2F382F2E

The DNA Diagnostics Market was valued at USD 13.59 billion in 2025 and is projected to grow to USD 14.77 billion in 2026, with a CAGR of 9.52%, reaching USD 25.70 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.59 billion
Estimated Year [2026] USD 14.77 billion
Forecast Year [2032] USD 25.70 billion
CAGR (%) 9.52%

A contemporary introduction to the DNA diagnostics ecosystem that frames scientific advances, regulatory shifts, and operational pressures reshaping diagnostic decisions

The introduction frames the contemporary DNA diagnostics landscape by highlighting the converging scientific, regulatory, and technological forces that are shaping diagnostic practice and research. Over recent years, advances in sequencing chemistry and bioinformatic pipelines have accelerated diagnostic throughput and precision, while regulatory agencies have evolved frameworks that emphasize analytical validity, clinical utility, and post-market surveillance. At the same time, laboratory workflows are adapting to balance high-complexity testing with pressures for faster turnaround times and cost containment.

This section positions stakeholders to understand how operational realities, including supply chain robustness and laboratory informatics, interact with clinical demand. It also outlines how patient expectations and payor scrutiny are prompting providers to justify diagnostic pathways with clearer evidence of clinical benefit. Taken together, these dynamics create both opportunities for innovation and imperatives for rigorous validation. As a result, leaders across diagnostics, healthcare delivery, and research must align technology investments, regulatory strategy, and clinical evidence generation to realize the promise of modern DNA-based testing.

How converging molecular technologies, expanded clinical applications, and integrated digital platforms are catalyzing systemic change across diagnostics and care pathways

Transformative shifts are underway across the DNA diagnostics ecosystem, driven by technological maturation and evolving clinical paradigms. Sequencing platforms, particularly next-generation sequencing alongside traditional Sanger approaches, now coexist with established molecular methods such as polymerase chain reaction, microarray technologies, and fluorescence in situ hybridization, enabling laboratories to select tools based on throughput, resolution, and clinical context. These technological choices influence downstream workflows, from sample preparation to data interpretation, and require parallel development of robust bioinformatics and quality-control processes.

Concurrently, applications have broadened to include complex areas like oncology testing and pharmacogenomics as well as classic clinical arenas such as genetic testing, prenatal testing, infectious disease testing, and newborn screening. Within genetic testing, subdomains such as carrier screening, diagnostic testing, newborn screening, and predictive testing each demand distinct validation and reporting standards. Product ecosystems have expanded to encompass consumables, instruments, kits, and increasingly sophisticated software and services, including cloud services, data analysis tools, and laboratory information management systems. This shift toward integrated solutions is reshaping vendor strategies and laboratory procurement decisions. Finally, end users ranging from diagnostic laboratories to hospitals and clinics and research institutes are recalibrating their capabilities to harness multi-modal testing, driving consolidation, strategic partnerships, and investments in workforce training and digital infrastructure.

Assessing the operational and strategic consequences of United States tariff adjustments in 2025 for supply chain resilience and procurement planning across diagnostics

The introduction of new tariff measures in the United States for 2025 adds a layer of complexity to global supply chains and procurement strategies in DNA diagnostics. Tariff changes alter the relative cost structure of imported instruments, reagents, and specialized consumables, which in turn affects decisions about sourcing, inventory buffers, and local manufacturing investments. Suppliers and laboratory operators must therefore reassess vendor contracts, evaluate alternative sourcing corridors, and consider the implications for long-term supplier relationships.

Beyond immediate cost pressures, tariffs can accelerate strategic choices such as reshoring certain manufacturing steps, qualifying additional regional suppliers, or negotiating for price adjustments and contractual protections. They also influence capital allocation decisions, as laboratories weigh the impact of higher import costs against the need to modernize instrumentation or expand sequencing capacity. In parallel, service providers and software vendors may face indirect effects through altered customer purchasing power and shifting priorities for capital expenditure. Consequently, organizations that proactively model tariff scenarios and engage in scenario planning will maintain operational resilience and preserve delivery commitments to clinicians and patients.

A nuanced segmentation analysis revealing how technologies, clinical applications, product offerings, and end-user needs collectively determine adoption trajectories and investment priorities

Key segmentation insights reveal how differentiated technology platforms, clinical applications, product portfolios, and end-user types are shaping adoption pathways and operational models. In terms of technology, legacy and targeted techniques such as fluorescence in situ hybridization and microarray continue to serve defined diagnostic niches while polymerase chain reaction retains dominance for rapid, high-sensitivity tests; sequencing modalities-encompassing both next-generation sequencing and Sanger sequencing-are expanding into comprehensive genomic profiling and confirmatory testing, respectively, with each approach bringing distinct throughput and informatics requirements.

Across applications, genetic testing remains multifaceted: carrier screening, diagnostic testing, newborn screening, and predictive testing each follow unique clinical and regulatory trajectories that influence laboratory validation and reporting. Infectious disease testing and prenatal testing demand rapid turnaround and robust quality controls, whereas oncology testing and pharmacogenomics rely increasingly on complex panels and iterative bioinformatic interpretation. Product type segmentation highlights the growing interdependence of consumables, instruments, kits, and software and services; cloud services, data analysis tools, and laboratory information management systems now play crucial roles in enabling scalable workflows and regulatory traceability. Finally, end users such as diagnostic laboratories, hospitals and clinics, and research institutes differ in scale, accreditation requirements, and resource allocations, shaping purchasing cycles and preferences for integrated solutions, managed services, or in-house development.

Comparative regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence adoption, regulation, and supply strategies in diagnostics

Regional dynamics continue to exert strong influence on technology deployment, regulatory approaches, and collaborative ecosystems across the DNA diagnostics landscape. In the Americas, mature clinical networks and well-established reimbursement pathways support broad adoption of advanced genomic testing, yet cost pressures and evolving payer expectations necessitate clear evidence of utility and operational efficiency. Clinical laboratories in this region frequently engage in cross-border sourcing, collaborative research, and public-private partnerships that accelerate translational work and diagnostic validation.

In Europe, the Middle East & Africa, regulatory harmonization efforts and variable infrastructure capacities create a mosaic of opportunities and challenges; certain national health systems prioritize genomic medicine investments, while others emphasize decentralized diagnostics and capacity-building programs. Regional supply chain strategies and public procurement practices play significant roles in shaping adoption. In Asia-Pacific, rapid investment in sequencing capacity, growing diagnostic R&D hubs, and rising healthcare demand are driving technology uptake, with specific markets emphasizing local manufacturing and regulatory adaptation. Collectively, these regions present distinct strategic imperatives for manufacturers, laboratory networks, and service providers seeking to align product portfolios with regional clinical needs and regulatory frameworks.

Strategic corporate behaviors in diagnostics that combine R&D leadership, platform integration, and collaborative partnerships to accelerate clinical uptake and commercial resilience

Companies operating in DNA diagnostics are differentiating through a mix of technology leadership, strategic partnerships, and services-oriented business models. Industry leaders invest heavily in R&D to refine sequencing chemistries, enhance assay sensitivity, and streamline sample-to-result workflows. At the same time, software vendors and integrators are focusing on cloud-enabled analytics, interoperability with laboratory information systems, and compliance-ready data governance to support multi-site deployments and regulated reporting.

Across the competitive landscape, several trends merit attention: firms that combine instrument platforms with consumables and recurring-revenue kit offerings strengthen customer lock-in, while those that pursue modular, open-platform strategies appeal to laboratories seeking flexibility. Strategic collaborations between manufacturers and clinical networks accelerate real-world evidence generation and support payer engagement. Emerging companies often concentrate on niche clinical applications or disruptive assay formats, forcing incumbents to reconsider product roadmaps. Additionally, M&A activity and cross-sector partnerships-particularly those that pair diagnostics with digital health and therapeutic developers-are reshaping competitive boundaries and creating new channels for clinical adoption.

Actionable strategic recommendations for diagnostic leaders to fortify supply chains, integrate digital platforms, and align clinical evidence with commercialization objectives

Industry leaders should adopt pragmatic strategies that balance near-term operational resilience with long-term innovation. First, prioritize diversified sourcing and flexible procurement clauses to insulate operations from tariff volatility and supply chain disruptions. This should be complemented by targeted investments in local or regional manufacturing capabilities for high-risk consumables and critical instrument components. Second, accelerate integration of cloud services, data analysis tools, and laboratory information management systems to reduce turnaround times, improve quality control, and enable scalable multi-site operations. Third, design clinical evidence programs tailored to distinct application segments-such as carrier screening, oncology testing, and infectious disease testing-to satisfy both regulatory requirements and payer expectations.

Moreover, cultivate partnerships with hospitals, diagnostic laboratories, and research institutes to co-develop workflows and gather real-world performance data. Implement pricing and service models that reflect the total cost of ownership for customers, including support, software updates, and data management. Finally, invest in workforce development-upskilling laboratory personnel in bioinformatics and quality systems-to ensure that organizations can extract full value from advanced sequencing and integrated diagnostics platforms. Together, these steps will support sustainable growth while maintaining clinical credibility and operational agility.

A transparent, reproducible research approach that integrates primary stakeholder engagement and secondary evidence synthesis to validate diagnostic technology insights

The research methodology combines structured primary engagement with targeted secondary analysis to ensure robust, reproducible insights. Primary inputs included in-depth interviews with laboratory directors, clinical geneticists, procurement leaders, and senior R&D executives to capture operational constraints, validation practices, and adoption drivers. These qualitative engagements were complemented by workshops with instrument developers and software providers to assess integration challenges and evolving product roadmaps.

Secondary analysis synthesized regulatory guidance, peer-reviewed literature, and manufacturer technical documentation to validate technological capabilities and testing pathways. Data integrity was ensured through triangulation across multiple sources and through structured expert review panels that reconciled divergent viewpoints. Segmentation logic was applied consistently to map technologies-such as fluorescence in situ hybridization, microarray, polymerase chain reaction, and sequencing including next-generation sequencing and Sanger sequencing-to clinical applications and product types. Regional analysis incorporated policy trends, procurement practices, and infrastructure factors to contextualize deployment scenarios. Throughout, transparency and repeatability guided both data collection and analytic workflows.

A conclusive synthesis emphasizing the imperative to align technical innovation, regulatory strategy, and commercial execution to achieve durable clinical impact

In conclusion, DNA diagnostics stands at an inflection point where technical capability, regulatory evolution, and commercial strategy must align to realize clinical value. Laboratories and product developers that prioritize interoperability, rigorous clinical validation, and adaptive supply-chain strategies will outperform peers in delivering reliable, clinically actionable results. The interplay between established molecular methods and expanding sequencing applications creates diverse pathways for innovation, but success depends on translating technical advances into validated, reimbursable clinical services.

Looking ahead, resilient organizations will combine operational discipline with strategic partnerships, invest in digital infrastructure and workforce skills, and maintain proactive engagement with regulators and payers. By doing so, they will convert scientific progress into measurable improvements in patient care while sustaining competitive positioning in a rapidly evolving ecosystem. The momentum toward integrated diagnostics and data-driven decision-making offers clear opportunities for those who act deliberately and collaboratively.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA Diagnostics Market, by Technology

  • 8.1. Fluorescence In Situ Hybridization
  • 8.2. Microarray
  • 8.3. Polymerase Chain Reaction
  • 8.4. Sequencing
    • 8.4.1. Next Generation Sequencing
    • 8.4.2. Sanger Sequencing

9. DNA Diagnostics Market, by Application

  • 9.1. Genetic Testing
    • 9.1.1. Carrier Screening
    • 9.1.2. Diagnostic Testing
    • 9.1.3. Newborn Screening
    • 9.1.4. Predictive Testing
  • 9.2. Infectious Disease Testing
  • 9.3. Oncology Testing
  • 9.4. Pharmacogenomics
  • 9.5. Prenatal Testing

10. DNA Diagnostics Market, by Product Type

  • 10.1. Consumables
  • 10.2. Instruments
  • 10.3. Kits
  • 10.4. Software And Services
    • 10.4.1. Cloud Services
    • 10.4.2. Data Analysis Tools
    • 10.4.3. Laboratory Information Management Systems

11. DNA Diagnostics Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals And Clinics
  • 11.3. Research Institutes

12. DNA Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. DNA Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. DNA Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States DNA Diagnostics Market

16. China DNA Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Adaptive Biotechnologies
  • 17.7. Agilent Technologies, Inc.
  • 17.8. ARUP Laboratories
  • 17.9. Becton, Dickinson and Company
  • 17.10. Bio-Rad Laboratories, Inc.
  • 17.11. BioMerieux
  • 17.12. Danaher Corporation
  • 17.13. DNA Diagnostic A/S
  • 17.14. Eurofins
  • 17.15. Exact Sciences Corporation
  • 17.16. F. Hoffmann-La Roche Ltd.
  • 17.17. Hologic, Inc.
  • 17.18. Illumina, Inc.
  • 17.19. Invitae Corporation
  • 17.20. Laboratory Corporation of America Holdings
  • 17.21. Luminex Corporation
  • 17.22. Myriad Genetics
  • 17.23. Natera, Inc.
  • 17.24. Oxford Nanopore Technologies PLC
  • 17.25. Promega Corporation
  • 17.26. QIAGEN GmbH
  • 17.27. Quest Diagnostics
  • 17.28. Siemens Healthineers
  • 17.29. Sysmex Corporation
  • 17.30. Thermo Fisher Scientific Inc.
  • 17.31. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DNA DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DNA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DNA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY ONCOLOGY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY ONCOLOGY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY ONCOLOGY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CLOUD SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CLOUD SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CLOUD SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY LABORATORY INFORMATION MANAGEMENT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY LABORATORY INFORMATION MANAGEMENT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY LABORATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS DNA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 161. GCC DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 163. GCC DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 165. GCC DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. G7 DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. G7 DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 185. G7 DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 187. G7 DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 189. G7 DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NATO DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. NATO DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. NATO DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 193. NATO DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. NATO DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 195. NATO DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. NATO DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA DNA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)